Please select the option that best describes you:
Which patients with primary, early-stage NSCLC would you utilize immunotherapy in conjunction with SBRT?
This post refers to the recently published RCT by Chang et al., PMID 37478883 investigating lung SBRT with vs. without 4 months of nivolumab for early stage, primary NSCLC.
What subset of patients may be appropriate for this approach now?
Answer from: Radiation Oncologist at Academic Institution
The trial from Chang et al., PMID 37478883 testing SBRT +/- IO for early-stage NSCLC was a randomized phase II trial. Although very exciting results, it's not a phase III trial and does not technically change management. IO agents are not FDA-approved in this setting yet! There are at least 2 phase ...
Sign in or Register to read more